Haleon plc Stock 12‑Month Price Target Cut to $11.07, Implies 11% Upside

Haleon plc's average stock price target was reduced from $11.15 to $11.07 by 16 analysts, with a range of $7.85 to $13.62. This implies an 11% upside from the Oct. 28 closing price. The consensus rating remains 'Buy' among 18 analysts, with 11 Buys, 5 Holds, and 2 Sells.

Original reporting
Published Oct 29, 2026, 7:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 7:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Haleon plc Stock 12‑Month Price Target Cut to $11.07, Implies 11% Upside — source image
Decision brief

The 30-second read

$HLNNeutralLow
01

Why it matters

The target reduction may lead to slight buying pressure if traders believe the stock is still undervalued, but the effect is expected to be muted.

02

Market read

A small analyst price‑target revision with limited immediate trading impact.

03

What to watch

Potential hidden risks in Haleon's pipeline or cost structure not reflected in the modest target change.

Relevance 5/10Novelty 5/10Timing: post‑market today

Background

Haleon plc is a consumer‑health company listed on NYSE under ticker HLN. The article reports a recent analyst consensus price‑target adjustment.

Company-level read

Ticker impact

$HLNNeutralMedium confidence
Context

Analyst price target for Haleon plc was lowered to $11.07, indicating a modest upside of ~11% from the current price.

Expected impact

modest upside as traders price in the 11% upside implied by the new target

Evidence & confidence

Target revisions are a common catalyst; the change is small and the consensus remains a Buy, limiting immediate price move.

Market effects

Minor impact on consumer health & personal care sector as analysts adjust expectations.

Limited to US and European markets where Haleon trades.

Low; the revision does not affect broader market indices.

Counterpoint

Some investors may view the target cut as a buying opportunity given the still‑positive upside.

Key entities

  • Haleon plc

    Consumer‑health products maker, ticker HLN.

Related articles

$HLNHigh

Haleon margin reset and weak sales beyond oral care prompt Jefferies downgrade to 'hold'

Haleon PLC (HLN) was downgraded to 'hold' by Jefferies, which cited weak sales outside oral health and cut its price target 20% to 320p. Haleon guided to 2.5% organic sales growth, down from 4%, and Q3 growth missed consensus. Jefferies expects a 150-basis-point margin reduction by 2027 and cut its 2027 EPS forecast 11% to 19.9p. Shares trade at their lowest valuation since mid-2022.

$HLNMed

Deutsche Bank upgrades Haleon stock rating on valuation reset

Deutsche Bank upgraded Haleon (NYSE:HLN) to Hold from Sell, lowering its price target to GBP3.10. The stock has fallen 16.6% in a week, near its 52-week low. The firm cited weak growth due to industry changes and poor execution. InvestingPro notes the stock is undervalued. Haleon's Q3 2026 results missed expectations, but it maintained its full-year profit outlook.

$HLNHighAI 8/10

Haleon Sinks 14% on Growth Downgrade Despite £500 Million Buyback: “Q3 Was Below Our Expectations”

Haleon shares fell 14% after lowering its 2026 organic revenue growth outlook to around 2.5% from 3%-5%. The company announced a £500 million buyback, but it failed to offset investor concerns. CEO Brian McNamara stated Q3 results were below expectations, with organic revenue growth at 2.6%, down from 3.1% in Q2. The company's medium-term growth goal remains 4%-6%.

$GOOGLHighAI 8/10

European stocks rally after ECB and Fed holds

European stocks rose on Thursday after the ECB and Fed left interest rates unchanged. The FTSE 100 gained 0.3%, while the CAC 40 and DAX 40 climbed 1.1% and 1.3% respectively. ECB President Christine Lagarde announced her resignation. Alphabet shares fell 12% after missing earnings expectations. Shell reported better-than-expected results, while Haleon cut its revenue guidance.